News Release

Shareholder Tools

AmerisourceBergen Reports First Quarter Fiscal Year 2014 Results

Reiterates Expectations for Fiscal 2014 Adjusted Diluted EPS from
Continuing Operations to be in the range of $3.60 to $3.73

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jan. 23, 2014--
AmerisourceBergen Corporation (NYSE:ABC) today reported that in its
fiscal year 2014 first quarter ended December 31, 2013, adjusted diluted
earnings per share from continuing operations increased 9.6 percent to
$0.80. Revenue increased 38.5 percent to $29.2 billion in the quarter.
On the basis of U.S. generally accepted accounting principles (GAAP),
diluted earnings per share from continuing operations were $0.21 for the
December quarter of fiscal 2014. In the tables that follow, we present
our GAAP results as well as a reconciliation of GAAP income from
continuing operations to adjusted non-GAAP income from continuing
operations.

“In our December quarter, we delivered solid results as we onboarded
substantial new business,” said Steven H. Collis, AmerisourceBergen
President and Chief Executive Officer. “We performed well operationally,
made meaningful progress through a significant working capital
transition, and positioned ourselves well to meet our objectives for the
fiscal year.”

In addition, we calculate our adjusted earnings per share for each
period using a diluted weighted average share count, which excludes the
accounting dilution resulting from the impact of the unexercised equity
warrants.

Summary of Adjusted Quarterly Results

Revenue: In the first quarter of fiscal
2014, revenue was $29.2 billion, up 38.5 percent compared to the same
quarter in the previous fiscal year, reflecting a 46 percent increase
in AmerisourceBergen Drug Corporation (ABDC) revenue, and an 8 percent
increase in AmerisourceBergen Specialty Group (ABSG) revenue.

Gross Profit: Gross profit in the fiscal
2014 first quarter was $724.8 million, an 11.6 percent increase over
the same period in the previous year, driven by strong revenue growth
and solid performance relating to generic pharmaceuticals in ABDC,
offset by a substantial increase in lower margin brand business. Gross
profit as a percentage of revenue decreased 60 basis points to 2.48
percent.

Operating Expenses: In the first quarter
of fiscal 2014, operating expenses were $402.1 million, up 13.8
percent over the same period in the last fiscal year. The increase in
operating expenses in the quarter was due primarily to costs
associated with onboarding the new Walgreen Co. business. Operating
expenses as a percentage of revenue in the fiscal 2014 first quarter
were 1.38 percent compared with 1.68 percent for the same period in
the previous fiscal year.

Operating Income: In the fiscal 2014
first quarter, operating income of $322.7 million was up 8.9 percent
versus the prior year, as the increase in gross profit was offset in
part by the increase in operating expenses. Operating income as a
percentage of revenue decreased 30 basis points to 1.11 percent in the
fiscal 2014 first quarter compared to the previous year’s first
quarter.

Tax Rate: The effective tax rate for the
first quarter of fiscal 2014 was 38.2 percent, up from 37.8 percent in
the previous fiscal year’s first quarter. Going forward, we expect our
annualized effective tax rate to be in the low 38 percent range.

Earnings Per Share: Diluted earnings per
share from continuing operations were up 9.6 percent to $0.80 in the
first quarter of fiscal year 2014 compared to $0.73 in the previous
fiscal year’s first quarter, driven by the increase in operating
income.

Shares Outstanding: Diluted weighted
average shares outstanding for the first quarter of fiscal year 2014
were 235.4 million, a slight decrease versus the prior year as share
repurchases offset option exercises.

Segment Discussion

The Pharmaceutical Distribution segment includes both AmerisourceBergen
Drug Corporation and AmerisourceBergen Specialty Group. Other includes
AmerisourceBergen Consulting Services (ABCS) and World Courier.

Pharmaceutical Distribution Segment

In the first fiscal quarter of 2014, Pharmaceutical Distribution
revenues were $28.6 billion, an increase of 39 percent compared to the
same quarter in the prior year. ABDC revenues increased 46 percent, due
primarily to the onboarding of the new Walgreens branded pharmaceuticals
business and increased sales to our large PBM customer, as well as other
large customers. ABSG revenues increased 8 percent, which was driven by
strong performance in our blood products, vaccine and physician office
distribution businesses. Intrasegment revenues between ABDC and ABSG
have been eliminated in the presentation of total Pharmaceutical
Distribution revenue. Total intrasegment revenues were $976.8 million
and $863.8 million in the quarters ended December 31, 2013 and 2012,
respectively.

Operating income of $286.8 million in the December quarter of fiscal
2014 increased 8 percent compared to the same period in the previous
year due to the new Walgreens branded pharmaceuticals business in ABDC,
strong contributions from generics, and solid performance in ABSG, as a
decline in performance in our community oncology business was offset by
strong performance in our physician office, vaccine and blood products
distribution businesses.

Other

Revenues in Other were $604.1 million in the first quarter of fiscal
2014, an increase of 20 percent over the same period in the prior year.
Operating income increased 21 percent to $36.0 million in the first
quarter of fiscal 2014, driven by strong performance in World Courier.

Fiscal Year 2014 Expectations

AmerisourceBergen continues to expect adjusted diluted earnings per
share from continuing operations in fiscal year 2014 to be in the range
of $3.60 to $3.73, a 12 percent to 16 percent increase over fiscal 2013.
We have increased our revenue growth expectations to a range of 30
percent to 34 percent, and continue to expect adjusted operating income
growth in the 12 percent to 16 percent range. We now expect adjusted
operating margin to decline in the 20 to 23 basis points range due to
the onboarding of significant new lower margin business and growth in
brand pharmaceutical business with our large customers. We continue to
expect to generate free cash flow in the range of $500 to $700 million,
with capital expenditures in the $300 million range; and to spend
approximately $500 million in share repurchases, subject to market
conditions.

Conference Call

The Company will host a conference call to discuss the results at 11:00
a.m. Eastern Time on January 23, 2014.

Participating in the conference call will be:

Steven H. Collis, President & Chief Executive Officer

Tim G. Guttman, Senior Vice President & Chief Financial Officer

The dial-in number for the live call will be (612) 234-9960. No access
code is required. The live call will also be webcast via the Company’s
website at www.amerisourcebergen.com.
Users are encouraged to log on to the webcast approximately 10 minutes
in advance of the scheduled start time of the call.

Replays of the call will be made available via telephone and webcast. A
replay of the webcast will be posted on www.amerisourcebergen.com
approximately two hours after the completion of the call and will remain
available for thirty days. The telephone replay will also be available
approximately two hours after the completion of the call and will remain
available for seven days. To access the telephone replay from within the
US, dial (800) 475-6701. From outside the US, dial (320) 365-3844. The
access code for the replay is 313989.

About AmerisourceBergen

AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel. With over $100 billion in annualized revenue, AmerisourceBergen
is headquartered in Valley Forge, PA, and employs approximately 13,000
people. AmerisourceBergen is ranked #32 on the Fortune 500 list. For
more information, go to www.amerisourcebergen.com.

Certain of the statements contained in this news release are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,”
“could,” “should,” “can,” “will,” “project," “intend,” “plan,”
“continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,”
“estimate,” “anticipate,” “may,” “possible,” “assume,” variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management’s
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; the retention of key customer or supplier
relationships under less favorable economics; changes in customer mix;
customer delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in branded and/or generic pharmaceutical
manufacturers’ pricing and distribution policies or practices; adverse
resolution of any contract or other dispute with customers or suppliers;
federal and state government enforcement initiatives to detect and
prevent suspicious orders of controlled substances and the diversion of
controlled substances, federal and state prosecution of alleged
violations of related laws and regulations, and any related litigation,
including shareholder derivative lawsuits or other disputes relating to
our distribution of controlled substances; qui tam litigation for
alleged violations of fraud and abuse laws and regulations and/or any
other laws and regulations governing the marketing, sale, purchase
and/or dispensing of pharmaceutical products or services and any related
litigation, including shareholder derivative lawsuits; changes in
federal and state legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare, and the effect of such changes on our
customers; changes in regulatory or clinical medical guidelines and/or
labeling for the pharmaceutical products we distribute, including
certain anemia products; price inflation in branded and generic
pharmaceuticals and price deflation in generics; greater or less than
anticipated benefit from launches of the generic versions of previously
patented pharmaceutical products; significant breakdown or interruption
of our information technology systems; our inability to realize the
anticipated benefits of the implementation of an enterprise resource
planning (ERP) system; interest rate and foreign currency exchange rate
fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and
regulations; economic, business, competitive and/or regulatory
developments outside of the United States; risks associated with the
strategic, long-term relationship among Walgreen Co., Alliance Boots
GmbH, and AmerisourceBergen, the occurrence of any event, change or
other circumstance that could give rise to the termination,
cross-termination or modification of any of the transaction documents
among the parties (including, among others, the distribution agreement
or the generics agreement), an impact on our earnings per share
resulting from the issuance of the Warrants, an inability to realize
anticipated benefits (including benefits resulting from participation in
the Walgreens Boots Alliance Development GmbH joint venture), the
disruption of AmerisourceBergen’s cash flow and ability to return value
to its stockholders in accordance with its past practices, disruption of
or changes in vendor, payer and customer relationships and terms, and
the reduction of AmerisourceBergen’s operational, strategic or financial
flexibility; the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our
inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax laws or legislative
initiatives that could adversely affect our tax positions and/or our tax
liabilities or adverse resolution of challenges to our tax positions;
increased costs of maintaining, or reductions in our ability to
maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; natural disasters or
other unexpected events that affect our operations; and other economic,
business, competitive, legal, tax, regulatory and/or operational factors
affecting our business generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) and Item 1 (Business) in the
Company’s Annual Report on Form 10-K for the fiscal year ended September
30, 2013 and elsewhere in that report and (ii) in other reports.

AMERISOURCEBERGEN CORPORATION

FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

Three

Three

Months Ended

Months Ended

December 31,

% of

December 31,

% of

%

2013

Revenue

2012

Revenue

Change

Revenue

$29,176,362

100.00

%

$21,059,811

100.00

%

38.5

%

Cost of goods sold

28,488,137

20,398,983

39.7

%

Gross profit (1)

688,225

2.36

%

660,828

3.14

%

4.1

%

Operating expenses:

Distribution, selling and administrative

364,060

1.25

%

320,700

1.52

%

13.5

%

Depreciation and amortization

43,950

0.15

%

38,684

0.18

%

13.6

%

Warrants

116,297

0.40

%

-

-

%

Employee severance, litigation and other

4,302

0.01

%

2,004

0.01

%

Total operating expenses

528,609

1.81

%

361,388

1.72

%

46.3

%

Operating income

159,616

0.55

%

299,440

1.42

%

-46.7

%

Other income

(597

)

-

%

(23

)

-

%

Interest expense, net

18,832

0.06

%

18,525

0.09

%

1.7

%

Income before income taxes

141,381

0.48

%

280,938

1.33

%

-49.7

%

Income taxes

92,450

0.32

%

106,317

0.50

%

-13.0

%

Income from continuing operations

48,931

0.17

%

174,621

0.83

%

-72.0

%

Loss from discontinued operations, net of income taxes

(7,546

)

(6,010

)

Net income

$41,385

0.14

%

$168,611

0.80

%

Basic earnings per share:

Continuing operations

$0.21

$0.75

-72.0

%

Discontinued operations

(0.03

)

(0.03

)

Rounding

-

0.01

Total

$0.18

$0.73

Diluted earnings per share:

Continuing operations

$0.21

$0.74

-71.6

%

Discontinued operations

(0.03

)

(0.03

)

Rounding

(0.01

)

-

Total

$0.17

$0.71

Weighted average common shares outstanding:

Basic

230,277

232,361

Diluted (2)

237,012

235,992

0.4

%

(1)

Includes a $21.0 million gain from antitrust litigation
settlements and a $57.6 million LIFO expense charge in the three
months ended December 31, 2013. Includes a $12.3 million gain from
antitrust litigation settlements and a $1.2 million LIFO expense
charge in the three months ended December 31, 2012.

(2)

Includes the dilutive effect of stock options, restricted stock,
restricted stock units and the Warrants issued to Walgreens and
Alliance Boots.

(1) The income tax rate applicable to Warrant expense was
lower than our normal income tax rate as a portion of the Warrant
expense is not tax deductible. The income tax rate on Warrant
expense will vary by quarter depending upon the expected quarterly
changes in the fair value of the Warrants.

(2) For the reconciling items and for the Non-GAAP
presentation, diluted earnings per share and diluted weighted
average common shares outstanding have been adjusted to exclude
the impact of the accounting dilution from the unexercised
Warrants.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..